

BLAU FARMACÊUTICA S.A.

Publicly Held Company
NIRE 35.300.416.406
CVM Code No. 2462-7

NOTICE TO SHAREHOLDERS**Live Participation**

BLAU FARMACÊUTICA S.A. (Ticker: **BLAU3**; "**Blau**" or "**Company**"), in compliance with the provisions of CVM Resolution No. 44/21 and Circular Letter No. 7/2020 – CVM/SEP, informs its shareholders and the market in general the participation of Mr. Douglas Rodrigues, CFO and IRO, in a live event in Portuguese with Simpla Invest, to be broadcast on May 21, at 8:00 pm.

List of topics to be addressed: history of the company and its growth trajectory, main lines of business, competitive positioning and strategy for the coming years.

Access can be made through the following YouTube link:

<https://youtube.com/live/7OsfsKtL4eI>

The Company is taking this opportunity to invite the market in general to participate in this event.

Cotia, May 20, 2026

Douglas Leandro Rodrigues
Chief Financial and Investor Relations Officer

About Blau Farmacêutica:

Blau is a leading multinational pharmaceutical company in the hospital segment and a pioneer in biotechnology in Brazil, with a portfolio of proprietary brands of highly complex medicines focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectious diseases, and several other therapeutic classes. Blau has an international presence, operating in Brazil and seven other Latin American countries (Argentina, Colombia, Chile, Ecuador, Mexico, Peru, and Uruguay), in addition to a plasma collection operation in the United States. It has a modern pharmaceutical industrial complex in Brazil, consisting of five industrial plants with state-of-the-art technology, dedicated to serving the local market and exports.